Mills Roger M, Hobbs Robert E
Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA.
Cleve Clin J Med. 2002 Mar;69(3):252-6. doi: 10.3949/ccjm.69.3.252.
Nesiritide (Natrecor), a synthetic formulation of B-type natriuretic peptide (BNP), is the first new parenteral agent to be approved for treating heart failure in more than a decade. In patients hospitalized with decompensated congestive heart failure, nesiritide promptly reduces pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and systemic vascular resistance, resulting in clinical improvement.
奈西立肽(心钠素)是B型利钠肽(BNP)的合成制剂,是十多年来首个被批准用于治疗心力衰竭的新型胃肠外给药制剂。在因失代偿性充血性心力衰竭住院的患者中,奈西立肽能迅速降低肺毛细血管楔压、肺动脉压、右心房压和全身血管阻力,从而使临床症状得到改善。